Aldeyra Therapeutics Inc [ALDX] stock is trading at $4.96, up 4.64%. An important factor to consider is whether the stock is rising or falling in short-term value. The ALDX shares have gain 3.33% over the last week, with a monthly amount drifted -4.25%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aldeyra Therapeutics Inc [NASDAQ: ALDX] stock has seen the most recent analyst activity on April 03, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $10 for it. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $26 on February 08, 2021. Berenberg initiated its recommendation with a Buy and recommended $32 as its price target on December 16, 2020. Jefferies started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $24. In a note dated October 16, 2020, BTIG Research initiated an Buy rating and provided a target price of $29 on this stock.
Aldeyra Therapeutics Inc [ALDX] stock has fluctuated between $2.71 and $6.55 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Aldeyra Therapeutics Inc [NASDAQ: ALDX] shares were valued at $4.96 at the most recent close of the market. An investor can expect a potential return of 141.94% based on the average ALDX price forecast.
Analyzing the ALDX fundamentals
Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -126.43%, Pretax Profit Margin comes in at -114.09%, and Net Profit Margin reading is -114.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.43 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.77 points at the first support level, and at 4.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.06, and for the 2nd resistance point, it is at 5.17.
Ratios To Look Out For
For context, Aldeyra Therapeutics Inc’s Current Ratio is 6.64. On the other hand, the Quick Ratio is 6.64, and the Cash Ratio is 1.64.
Transactions by insiders
Recent insider trading involved Machatha Stephen, Chief Development Officer, that happened on Aug 12 ’24 when 16041.0 shares were sold., Greenberg Bruce completed a deal on Aug 12 ’24 to sell 10834.0 shares. Meanwhile, Officer Greenberg Bruce bought 10834.0 shares on Aug 12 ’24.
